跳转至内容
Merck
CN

HCVD2MAG-67K

MILLIPLEX® Human Cardiovascular Disease Panel

Configurable Human CVD 10-Plex Panel 2

别名:

CVD assay snapshot, CVD multiplex product sheet, cardiovascular biomarker listing, cardiovascular biomarker profile, coagulation and inflammation detection kit, human CVD assay overview, human cardiovascular panel summary, human cardiovascular research tool, human vascular biomarker info, vascular inflammation biomarker panel

登录 查看组织和合同定价。

关于此项目

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000


产品名称

MILLIPLEX® Human Cardiovascular Disease Panel,

description

Configurable Human CVD 10-Plex Panel 2

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

assay range

inter-assay cv: <20%
intra-assay cv: <15%, accuracy: 88%
(Myoglobin), accuracy: 90%
(P-selectin), accuracy: 98%
(GDF-15), standard curve range: 0.0005-2.5 ng/mL
(GDF-15), standard curve range: 0.012-50 ng/mL
(Lipocalcin-2/NGAL), standard curve range: 0.024-100 ng/mL
(Myoglobin & MPO), standard curve range: 0.085-350 ng/mL
(sICAM-1), standard curve range: 0.122-500 ng/mL
(sVCAM-1), standard curve range: 0.244-1,000 ng/mL
(D-dimer, SAA & P-selectin), standard curve range: 1.221-5,000 ng/mL
(ADAMTS 13)

technique(s)

multiplexing: suitable

input

plasma
cell culture supernatant(s)

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

General description

Cardiovascular disease is closely linked to inflammation, endothelial dysfunction, oxidative stress, and coagulation abnormalities. This set of biomarkers—ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, and sVCAM-1—captures key indicators of vascular injury, immune activation, and thrombotic risk. These analytes are widely studied in the context of atherosclerosis, acute coronary syndromes, and systemic inflammation, making them highly relevant for translational and clinical cardiovascular research.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 10 analytes in human serum, plasma, or cell culture supernatants.

Analytes included: ADAMTS13, D-dimer S, GDF15, sICAM-1, Myeloperoxidase (MPO), Myoglobin, NGAL/Lipocalin-2, sP-Selectin, Serum Amyloid A, sVCAM-1Note: D-Dimer cannot be measured in plasma samples.

Assay Characteristics: Refer to assay protocol for details on cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Features:
  • Targets biomarkers involved in vascular inflammation, endothelial activation, and coagulation
  • Includes 10 analytes relevant to cardiovascular risk, oxidative stress, and immune response
  • Multiplex format enables simultaneous detection from minimal sample volume
  • Compatible with human serum and plasma samples
  • Designed for research in atherosclerosis, thrombosis, acute coronary syndromes, and systemic inflammation
Benefits:
  • Provides a comprehensive profile of cardiovascular and inflammatory biomarkers
  • Supports investigation of vascular injury, immune activation, and thrombotic mechanisms
  • Facilitates evaluation of therapeutic interventions and biomarker-based risk assessment
  • Enables high-throughput analysis with reduced sample and reagent use
  • Delivers reproducible, sensitive results for translational and clinical research

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.


Still not finding the right product?

Explore all of our products under


pictograms

Exclamation markEnvironment

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

存储类别

10 - Combustible liquids

wgk

WGK 3

法规信息

新产品

此项目有



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

Learn about biomarkers of cardiovascular disease (CVD) and discover how multiplex CVD panels, such as MILLIPLEX® multiplex assays, are being used to increase the efficiency of biomarker discovery for CVD research.

Uncover tips and tricks to multiplexing in this guide from the experts. Learn how you can enhance the power of your research with MILLIPLEX® multiplexing, including industry guidance for immunoassays, multiplexing tips, one-day MILLIPLEX® multiplex assays for limited lab time, and more.

查看所有相关内容

Alberto Soriano-Maldonado et al.
Journal of clinical medicine, 7(12) (2018-11-28)
This study assessed the effect of 12-week aerobic exercise on arterial stiffness (primary outcome), inflammation, oxidative stress, and cardiorespiratory fitness (secondary outcomes) in women with systemic lupus erythematosus (SLE). In a non-randomized clinical trial, 58 women with SLE were assigned
Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis.
Sigurdardottir, G; Ekman, AK; St?hle, M; Bivik, C; Enerback, C
Journal of the American Academy of Dermatology null
Emanuele Marzetti et al.
Frontiers in medicine, 1, 27-27 (2015-01-17)
Chronic, low-grade inflammation and declining physical function are hallmarks of the aging process. However, previous attempts to correlate individual inflammatory biomarkers with physical performance in older people have produced mixed results. Given the complexity of the inflammatory response, the simultaneous